Palvella Therapeutics, Inc. PVLA
175.92 USD +19.07 (+12.16%)
At closeNov 6, 2026, 4:00 PM EST
175.92 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
156.54 Day range 176.60
76.43 52-week range 175.92
- YTD
- +68.07%
- 1 year
- +123.73%
- Market cap
- 2.53B
- EPS (ttm)
- -4.85
- Shares out
- 14.41M
- Forward P/E
- -22.25
- YTD return
- +68.07%
- 1-year return
- +123.73%
- Volume
- 502.03K
- Avg volume
- 224.31K
- Open
- 158.01
- Previous close
- 156.85
- Day's range
- 156.54 – 176.60
- 52-week range
- 76.43 – 175.92
- Analysts
- Strong Buy
- Price target
- 228.40 (+29.8%)
- Earnings date
- Mar 30, 2027
5D +25.92 (+17.28%)
Key statistics
- Enterprise value
- 2.11B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 77.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.45M
- Total cash
- 250.58M
- Total debt
- 22.64M
- Return on equity
- -46.63%
- Short % of float
- 18.90%
- 50-day average
- 142.03
- 200-day average
- 128.04
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 228.40 +29.8% upside
Now 175.92
- Target (low)
- 205.00
- Target (mean)
- 228.40
- Target (high)
- 267.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy0
- Buy16
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 30, 2027
Expected Mar 30, 2027. Consensus EPS estimate -2.04.
Financials — quick view
PVLA Revenue — quarterly 0
PVLA Net income — quarterly -21.87M
PVLA EPS — quarterly -1.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2027 | Dec 30, 2026 | -1.83 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.78 | -1.70 | +0.08 | +4.49% |
| Aug 4, 2026 | Jun 30, 2026 | -1.17 | -1.52 | -0.35 | -29.91% |
| May 7, 2026 | Mar 31, 2026 | -0.90 | -1.20 | -0.30 | -33.33% |
| Mar 31, 2026 | Dec 31, 2025 | -0.91117 | -1.08 | -0.17 | -18.53% |
| Nov 11, 2025 | Sep 30, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 28, 2026 | Chardan Capital | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 21, 2026 | Chardan Capital | main | Buy | Buy |
| May 21, 2026 | Stephens & Co. | reit | Overweight | Overweight |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palvellatx.com
News
Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 
Palvella Therapeutics Q3 2026 Earnings Call Transcript - Palvella Therapeutics Q3 EPS $(1.70) Beats $(1.82) Estimate
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference 
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating 
Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday 
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246 
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations 
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
Your note
Sign in to keep a note on PVLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOIN KATHLEEN | Chief Operating Officer | Sale | Aug 18, 2026 | 0 |
| HERON ELAINE J | Director | Purchase | Feb 26, 2026 | 53,691 |
| JENKINS GEORGE M | Director | Sale | Oct 13, 2026 | 146,132 |
| KIRITSY CHRISTOPHER P | Director | Sale | Sep 1, 2026 | 250 |
| KORENBERG MATTHEW E | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 11, 2026 | 1,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 7.88% | 1,135,406 | 199.74M | Jun 29, 2026 |
| Jennison Associates LLC | 6.67% | 960,619 | 168.99M | Jun 29, 2026 |
| Blackrock Inc. | 6.37% | 918,357 | 161.56M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 6.12% | 882,400 | 155.23M | Jun 29, 2026 |
| First Light Asset Management, LLC | 5.36% | 771,901 | 135.79M | Jun 29, 2026 |
| BVF Inc. | 4.67% | 672,789 | 118.36M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.70% | 388,390 | 68.33M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.51% | 362,314 | 63.74M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.14% | 308,699 | 54.31M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.92% | 276,556 | 48.65M | Jul 30, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.61% | 231,484 | 40.72M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.47% | 212,225 | 37.33M | Sep 29, 2026 |